MedPath

This study will observe the effect of Omeprazole on patient reported outcomemeasures in acid peptic disease

Phase 4
Conditions
Health Condition 1: K279- Peptic ulcer, site unspecified, unspecified as acute or chronic, without hemorrhage or perforation
Registration Number
CTRI/2020/04/024624
Lead Sponsor
Dr Reddys Laboratories Ltd
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Subjects must voluntarily give consent in writing to participate in the

study by signing the Informed Consent Form (ICF)

2. Subjects of either sex diagnosed with acid peptic disease aged >=18

years and <=65 years.

3. Subject who has been prescribed omeprazole therapy as routine

clinical management as per Investigator discretion.

Exclusion Criteria

1. Hyper-sensitivity to any Proton pump inhibitor including omeprazole

in the past.

2. Participated in an investigational drug or investigational device study

within 30 days prior to the start of the study

3. Prior treatment for acid peptic disease histamine-2 receptor

antagonists or over the counter antacids during the week immediately

before the study

4. Any medical condition according to investigator which may interfere

with the treatment. Makes patient illegible for participation in study.

5. Planned surgical procedure during the duration of the study.

6. Women who are pregnant or breast-feeding and women who could

become pregnant during the study

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To evaluate Patient Assessment of Gastrointestinal Disorder Symptom Severity Index (PAGI-SYM) at Day 14Timepoint: Baseline, Day 14
Secondary Outcome Measures
NameTimeMethod
To evaluate Patient Assessment of Gastrointestinal Disorder Symptom <br/ ><br>Severity Index (PAGI-SYM) at Day 28Timepoint: Baseline, Day 28;To evaluate Patient overall treatment satisfaction on Day 28Timepoint: Day 28;To evaluate Patients overall treatment satisfaction on Day 14Timepoint: Day 14
© Copyright 2025. All Rights Reserved by MedPath